Optimizing adipose-derived stem cell therapy for diabetic foot ulcers

Figure 2 Wound closure in diabetic foot ulcer model mice and rats after treatment with adipose-derived mesenchymal stem cells. A: Schematic diagram of the animal experiment; B: Representative images of ulcers in diabetic foot ulcer (DFU) mice on days 7 and 14 after subcutaneous injection of low, medium, or high doses of adipose-derived mesenchymal stem cells (ADSCs) or vehicle; C: Statistical bar chart of the wound closure rate in DFU mice on day 7 after subcutaneous injection. The wound healing rate in the medium-dose group was significantly greater than that in the model group (P < 0.05), n = 14; D: Representative images of ulcers in DFU mice on days 7 and 14 after intramuscular injection of medium and high ADSC doses; E: Statistical chart of the wound closure rate in DFU mice on day 7 after intramuscular injection, n = 7; F: Representative images of ulcers in DFU rats on days 7 and 14 after subcutaneous injection of low and medium ADSC doses; G: Statistical chart of the wound closure rate in DFU rats on day 7 after subcutaneous injection. The wound healing rate in the medium-dose group was significantly greater than that in the model group (P < 0.05), n = 14. The data are presented as mean ± SD. STZ: Streptozotocin; ADSC: Adipose-derived mesenchymal stem cell. ^aP < 0.05 vs control, and ^bP < 0.05 vs model.